Valigen (US), Inc.
Records under this name other than patents Valigen (US), Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,035,991 | Non-Transgenic Herbicide Resistant Plants Formerly held Term ended Term ended Feb 21, 2024 · Medium confidence | Term ended | Term ended Feb 21, 2024 | Medium confidence |
| US 7,060,500 | Single-stranded oligodeoxynucleotide mutational vectors Formerly held Term ended Term ended Feb 17, 2021 · From the USPTO record | Term ended | Term ended Feb 17, 2021 | From the USPTO record |
| US 6,870,075 | Methods of making non-transgenic herbicide resistant plants Formerly held Term ended Term ended Jan 27, 2021 · From the USPTO record | Term ended | Term ended Jan 27, 2021 | From the USPTO record |
| US 8,106,259 | Compositions and methods for plant genetic modification Formerly held Term ended Term ended Oct 6, 2020 · From the USPTO record | Term ended | Term ended Oct 6, 2020 | From the USPTO record |
| US 6,211,351 | Chimeric mutational vectors Formerly held Term ended Term ended Oct 28, 2019 · From the USPTO record | Term ended | Term ended Oct 28, 2019 | From the USPTO record |
| US 6,271,360 | Single-stranded oligodeoxynucleotide mutational vectors Formerly held Term ended Term ended Aug 27, 2019 · From the USPTO record | Term ended | Term ended Aug 27, 2019 | From the USPTO record |
| US 6,479,292 | Genetic alteration in plants using single-stranded oligodeoxynucleotide vectors Formerly held Term ended Term ended Aug 27, 2019 · From the USPTO record | Term ended | Term ended Aug 27, 2019 | From the USPTO record |
| US 6,586,184 | Chimeric Mutational Vectors Formerly held Term ended Term ended Jun 17, 2018 · Medium confidence | Term ended | Term ended Jun 17, 2018 | Medium confidence |
| US 6,573,046 | Eukaryotic use of improved chimeric mutational vectors Formerly held Term ended Ended no later than May 12, 2018 · From the USPTO record | Term ended | Ended no later than May 12, 2018 | From the USPTO record |
| US 6,210,916 | Rec 2 kinase Lapsed on the fee record Ended Apr 3, 2009 · From the USPTO record | Lapsed on the fee record | Ended Apr 3, 2009 | From the USPTO record |